Hydrogen Therapy Shows Promise for COVID-19 Lung Complications
An Overview of SARS-CoV-2 (COVID-19) Infection and the Importance of Molecular Hydrogen as an Adjunctive Therapy
Research hubs: Respiratory System

- Evidence type
- Review or commentary
- Authors
- Grace Russell, Mubasher Rehman, Tyler LeBaron, David Veal, Emmanuel Adukwu, John Hancock
- Journal
- Reactive Oxygen Species
- Year
- 2020
- Study Type
- clinical
- Peer Reviewed
- Yes
- Cited by
- 13 (OpenAlex, as of November 2026)
- Country
- United Kingdom
TL;DR
Scientists think a gas called molecular hydrogen might help COVID-19 patients by calming down the body's extreme inflammatory response and protecting lung cells from damage. This could be an extra treatment to help people with severe breathing problems, but more research is needed to prove it actually works.
Key Finding
The review suggests molecular hydrogen may have potential as an additional treatment for COVID-19 by reducing excessive inflammation and harmful molecules in lung tissue, though this remains theoretical and requires clinical testing.
Summary
This is a review article that examines how molecular hydrogen (a gas that may reduce harmful inflammation in the body) could potentially help treat severe COVID-19 infections. The authors looked at existing research on both COVID-19 and molecular hydrogen's effects on inflammatory lung conditions, and they propose that hydrogen gas might help reduce the severe breathing problems that occur in serious COVID-19 cases.
Practical Takeaway
This is a review article proposing a hypothesis, not a study testing molecular hydrogen in COVID-19 patients. No human trials have been conducted yet, and the authors themselves call for further clinical investigation. Early-stage theoretical work like this cannot support any health recommendations.
Abstract (excerpt)
Abstract SARS-CoV-2 is an emerging β-coronavirus that causes COVID-19 disease that manifests primarily as a pulmonary infection that can rapidly progress into severe and acute respiratory distress in susceptible patients. Initial reports of severe pulmonary infections first arose in December 2019…